CliffBio
small molecule

BUTRANS

BUPRENORPHINE

Loss of exclusivity—loss of exclusivity
CompanyKNOA →See this company's full patent-cliff portfolio

Drug detail

Brand nameBUTRANS
Active ingredientBUPRENORPHINE
Strength5MCG/HR
Dosage formFILM, EXTENDED RELEASE
RouteTRANSDERMAL
ModalitySmall molecule
FDA approvalJune 2010
Marketing statusRX

More from KNOA

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

BUTRANS patent cliff — loss of exclusivity — | CliffBio